Skip to main content
. 2024 Feb 21;38(7):983–991. doi: 10.1097/QAD.0000000000003865

Fig. 1.

Participant disposition from baseline to Week 240 (OLE Week 96).

Fig. 1

aTwo participants randomized and not treated; bSeven participants randomized and not treated; cFive participants randomized and not treated. AE, adverse event; B/F/TAF, bictegravir/emtricitabine/tenofovir alafenamide; D/C, discontinuation; DTG/ABC/3TC, dolutegravir/abacavir/lamivudine; DTG+F/TAF, dolutegravir plus emtricitabine and tenofovir alafenamide; OLE, open-label extension.